Drugs facing NCE-1 in 2030
Drugs becoming eligible for first Paragraph IV ANDA filing in 2030
1. Adquey patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46792 | ACROTECH | NA |
Mar, 2028
(1 year, 4 months from now) | |
| US10588893 | ACROTECH | Ointment Containing An Oxazole Compound |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2031 |
Drugs and Companies using DIFAMILAST ingredient
NCE-1 date: 12 February, 2030
Market Authorisation Date: 12 February, 2026
Treatment: Method of treating atopic dermatitis
Dosage: OINTMENT
More Information on Dosage
ADQUEY family patents
2. Ambelvist patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10137209 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US12478696 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US11491245 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US10722601 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303573 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
Nov, 2039
(13 years from now) | |
| US11944690 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 12, 2031 |
Drugs and Companies using GADOQUATRANE ingredient
NCE-1 date: 12 June, 2030
Market Authorisation Date: 12 June, 2026
Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...
Dosage: SOLUTION
More Information on Dosage
AMBELVIST family patents
3. Baxfendy patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9353081 | ASTRAZENECA | Bicyclic Dihydroquinoline-2-One Derivatives |
Feb, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2031 |
Drugs and Companies using BAXDROSTAT ingredient
NCE-1 date: 15 May, 2030
Market Authorisation Date: 15 May, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
BAXFENDY family patents
4. Beqalzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11420968 | BEONE MEDICINES | Bcl-2 Inhibitors |
Apr, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2031 |
Drugs and Companies using SONROTOCLAX ingredient
NCE-1 date: 13 May, 2030
Market Authorisation Date: 13 May, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
BEQALZI family patents
5. Bysanti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570453 | VANDA | Method Of Predicting A Predisposition To Qt Prolongation |
Mar, 2028
(1 year, 4 months from now) | |
| US9157121 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(3 years from now) | |
| US10563259 | VANDA | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene |
Jul, 2030
(3 years from now) | |
| US12606869 | VANDA | Methods For The Administration Of Iloperidone |
Sep, 2030
(3 years from now) | |
| US8999638 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(3 years from now) | |
| US9074255 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(4 years from now) | |
| US9072742 | VANDA | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(4 years from now) | |
| US9074256 | VANDA | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(4 years from now) | |
| US9074254 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(5 years from now) | |
| US12478619 | VANDA | Method Of Treatment With Milsaperidone |
May, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 20, 2031 |
Drugs and Companies using MILSAPERIDONE ingredient
NCE-1 date: 20 February, 2030
Market Authorisation Date: 20 February, 2026
Treatment: Method for treatment of schizophrenia in adults by administering milsaperidone to a patient by lowering the dose after determining that the patient has a genetic predisposition for qt prolongation; Me...
Dosage: TABLET
More Information on Dosage
BYSANTI family patents
6. Cypsedo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9517988 | HAISCO | Phenol Derivative And Preparation Method And Use In Medicine Thereof |
May, 2034
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729666 | HAISCO | Use Of Gabaa Receptor Reinforcing Agent In Preparation Of Sedative And Anesthetic Medicament |
May, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2031 |
Drugs and Companies using CIPEPOFOL ingredient
NCE-1 date: 27 August, 2030
Market Authorisation Date: 27 August, 2026
Treatment: Inducing general anesthesia in adults undergoing surgery
Dosage: EMULSION
More Information on Dosage
CYPSEDO family patents
7. Etcamah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10590130 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US10131663 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10961241 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US12077530 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US12364689 | ASTRAZENECA | Dosage Regimen For The Treatment Of Cancer |
Sep, 2041
(14 years from now) | |
| US12453729 | ASTRAZENECA | Pharmaceutical Formulations |
Oct, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2031 |
Drugs and Companies using CAMIZESTRANT ingredient
NCE-1 date: 04 September, 2030
Market Authorisation Date: 04 September, 2026
Treatment: Treatment with a cdk4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) of hr-pos., her2-neg. locally advanced or metastatic breast cancer upon detection of esr1 mutation during aromatase inhibito...
Dosage: TABLET
More Information on Dosage
ETCAMAH family patents
8. Foundayo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50455 | ELI LILLY | NA |
Sep, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 01, 2031 |
Drugs and Companies using ORFORGLIPRON CALCIUM ingredient
NCE-1 date: 01 April, 2030
Market Authorisation Date: 01 April, 2026
Treatment: Treatment to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition by administering an effective am...
Dosage: TABLET
More Information on Dosage
FOUNDAYO family patents
9. Icotyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12552836 | JANSSEN | Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases |
Jul, 2039
(12 years from now) | |
| US11845808 | JANSSEN | Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases |
Jan, 2041
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11939361 | JANSSEN | Compositions Of Peptide Inhibitors Of Interleukin-23 Receptor |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 17, 2031 |
Drugs and Companies using ICOTROKINRA HYDROCHLORIDE ingredient
NCE-1 date: 17 March, 2030
Market Authorisation Date: 17 March, 2026
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
ICOTYDE family patents
10. Idvynso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7339053 | MERCK | 4'-C-Substituted-2-Haloadenosine Derivative |
May, 2027
(6 months from now) | |
| US8486975 | MERCK | Non-nucleoside reverse transcriptase inhibitors |
Aug, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 20, 2031 |
Drugs and Companies using DORAVIRINE; ISLATRAVIR ingredient
NCE-1 date: 20 April, 2030
Market Authorisation Date: 20 April, 2026
Treatment: Use of a complete two-drug regimen for the treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral reg...
Dosage: TABLET
More Information on Dosage
IDVYNSO family patents